Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
- PMID: 35666513
- PMCID: PMC9384217
- DOI: 10.1093/cid/ciac446
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Abstract
Background: Growing evidence indicates a causal relationship between SARS-CoV-2 infection and myocarditis. Post-authorization safety data have also identified myocarditis as a rare safety event following mRNA COVID-19 vaccination, particularly among adolescent and young-adult males after dose 2. We further evaluated the potential risk by querying the Moderna global safety database for myocarditis/myopericarditis reports among mRNA-1273 recipients worldwide.
Methods: Myocarditis/myopericarditis reports from 18 December 2020 to 15 February 2022 were reviewed and classified. The reported rate after any known mRNA-1273 dose was calculated according to age and sex, then compared with a population-based incidence rate to calculate observed-to-expected rate ratios (RRs).
Results: During the study period, 3017 myocarditis/myopericarditis cases among 252 million mRNA-1273 recipients who received at least 1 dose were reported to the Moderna global safety database. The overall reporting rate was 9.23 per 100 000 person-years, which was similar to the expected reference rate (9.0 cases per 100 000 person-years; RR [95% confidence interval (CI)], 1.03 [.97-1.08]). When stratified by sex and age, observed rates were highest for males aged <40 years, particularly those 18-24 years (53.76 per 100 000 person-years), which was higher than expected (RR [95% CI], 3.10 [2.68-3.58]). When considering only cases occurring within 7 days of a known dose, the observed rate was highest for males aged 18-24 years after dose 2 (4.23 per 100 000 doses administered).
Conclusions: Myocarditis/myopericarditis rates were not higher than expected for the overall population of mRNA-1273 recipients but were higher than expected in males aged 18-24 years, with most cases occurring 7 days after dose 2.
Keywords: COVID-19; SARS-CoV-2; myocarditis; pharmacovigilance; vaccination.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. All authors are employees of and shareholders in Moderna, Inc. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures
Similar articles
-
Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.JAMA Netw Open. 2022 Jun 1;5(6):e2218505. doi: 10.1001/jamanetworkopen.2022.18505. JAMA Netw Open. 2022. PMID: 35749115 Free PMC article.
-
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.BMJ. 2021 Dec 16;375:e068665. doi: 10.1136/bmj-2021-068665. BMJ. 2021. PMID: 34916207 Free PMC article.
-
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.JAMA. 2022 Jan 25;327(4):331-340. doi: 10.1001/jama.2021.24110. JAMA. 2022. PMID: 35076665 Free PMC article.
-
Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):921-925. doi: 10.1002/pds.5439. Epub 2022 Apr 16. Pharmacoepidemiol Drug Saf. 2022. PMID: 35404496 Free PMC article.
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
Cited by
-
Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine.Vaccines (Basel). 2022 Dec 8;10(12):2102. doi: 10.3390/vaccines10122102. Vaccines (Basel). 2022. PMID: 36560512 Free PMC article.
-
Vaccine-Triggered Acute Autoimmune Myocarditis: Defining, Detecting, and Managing an Apparently Novel Condition.J Am Heart Assoc. 2022 Nov;11(21):e026873. doi: 10.1161/JAHA.122.026873. Epub 2022 Oct 26. J Am Heart Assoc. 2022. PMID: 36285781 Free PMC article. No abstract available.
-
A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis.Am J Prev Med. 2023 Feb;64(2):275-284. doi: 10.1016/j.amepre.2022.09.002. Epub 2022 Sep 26. Am J Prev Med. 2023. PMID: 36266115 Free PMC article. Review.
References
Grant support
LinkOut - more resources
Full Text Sources
Miscellaneous